PRCT Procept Biorobotics Corp

UBS has initiated coverage on PROCEPT BioRobotics (PRCT) with a bullish outlook, projecting profitability by 2027 driven by expanding revenue, improved gross margins, and cost efficiencies. This positive sentiment reinforces existing analyst optimism regarding the company's Aquablation-based surgical robotics platform. Despite current losses and a high valuation, PROCEPT's reaffirmed 2025 and new 2026 revenue guidance support the bullish stance, though investors should acknowledge the risks associated with ongoing operating losses and high R&D spending.

This article, part of a larger list, highlights Procept BioRobotics Corp. (NASDAQ: PRCT) as a promising mid-cap healthcare stock under $50. Analysts are bullish on PRCT, with a high percentage of Buy ratings and a significant potential upside, driven by the company's growth prospects in surgical robotics for male urological health.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $53.40. Key financial results show revenue of $83.33M (up 42.6%) and an EPS loss of ($0.38) that beat estimates, though the company remains unprofitable. Institutional investors hold approximately 89.46% of the stock.

PROCEPT BioRobotics Corporation presented at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The presentation featured Matt O'Brien, one of Piper's med tech analysts, introducing PROCEPT BioRobotics. Full details of the transcript are reserved for subscribers.

Squarepoint Ops LLC significantly reduced its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 27.9% in Q2, while institutional investors collectively own about 89.46% of the company. Despite the selling, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $53.70. PROCEPT BioRobotics exceeded Q3 earnings and revenue estimates but remains unprofitable with negative margins.

Eventide Asset Management LLC significantly increased its stake in PROCEPT BioRobotics Corporation ($PRCT) by 33.1% in Q2, boosting its ownership to 468,476 shares valued at $27.0 million. This move contributes to the company's high institutional ownership of 89.46%, despite the company remaining unprofitable with negative net margins. Wall Street analysts maintain a "Moderate Buy" consensus rating for PROCEPT BioRobotics, with an average target price of $53.70, even after some target price adjustments.